Clegg, A. J., Bryant, Jackie, 1951-, Nicholson, T., McIntyre, Linda, De Broe, S., Gerard, Karen, 1961- and Waugh, Norman. (2001) Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease : a rapid and systematic review. Health Technology Assessment, Vol.5 (No.1). ISSN 1366-5278

Preview	Text WRAP_Waugh_dementia.pdf - Published Version Download (605Kb) | Preview
Preview	Text (Cover sheet) WRAP_waugh5_Coversheet_FinalVersion.pdf Download (200Kb) | Preview

Abstract

Alzheimer’s disease is the most common cause of dementia and is characterised by an insidious onset and slow deterioration. The estimated prevalence of Alzheimer’s disease for a standard health authority (500,000 people) is about 3330. Current service involves a wide range of agencies, and drug therapy for some patients.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School > Health Sciences
Library of Congress Subject Headings (LCSH):	Alzheimer's disease -- Treatment
Journal or Publication Title:	Health Technology Assessment
Publisher:	National Coordinating Centre for Health Technology Assessment
ISSN:	1366-5278
Date:	2001
Volume:	Vol.5
Number:	No.1
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
References:	1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–44. 2. Sandson TA, Price B. Diagnostic testing and dementia. Neurol Clin 1996;14:45–59. 3. Alzheimer’s Society. URL: http://146.101.3.157/index.html 4. Jagger C, Clarke M, Stone A. Predictors of survival with Alzheimer’s disease: a community based study. Psychol Med 1995;25:171–7. 5. Walsh J, Welch G, Larson E. Survival of outpatients with Alzheimer-type dementia. Ann Intern Med 1990;113:429–34. 6. Evans D, Smith LA, Scherr P, Albert M, Funkenstein HH, Hebert L. Risk of death from Alzheimer’s disease in a community population of older persons. Am J Epidemiol 1991;134:403–12. 7. Morbidity statistics from general practice, fourth national study, 1991–1992. London: ONS Crown Copyright; 1995. MB5 No 3. 8. Pitt FA, Chilcott J, Golightly P, Sykes J, Whittingham M. A review of the use of donepezil in the treatment of Alzheimer’s disease. Sheffield: Trent Institute for Health Services Research, Universities of Leicester, Nottingham and Sheffield; 1997. Guidance Notes for Purchasers No. 97/09. 9. Office for National Statistics. Estimated resident population of England and Wales at mid-1997 by sex and single year of age. London: HMSO; 1999. 10. Burns A, Luthert P, Levy R, Jacoby R, Lantos P. Accuracy of clinical diagnosis of Alzheimer’s disease. BMJ 1990;301:1026. 11. The investigation of dementia: results in 200 consecutive admissions. Lancet 1981:824–7. 12. Foster GR, Scott D, Payne S. The use of CAT scanning in dementia: a systematic review. Int J Technol Assess Health Care 1999;15(2):406–23. 13. Wright N, Lindesay J. A survey of memory clinics in the British Isles. Int J Geriatr Psychiatry 1995;10:379–85. 14. Memory clinics: past, present and future. Newsletter of the Psychologist’s Special Interest Group in Elderly People 1998; (63 Special edition). 15. Southampton Memory Clinic: important information for general practitioners. Southampton Community Health Services Trust; 1997. 16. Eccles M, Clarke,J, Livingstone M, Freemantle N, Mason J. North of England evidence-based guidelines development project: guidelines for the primary care management of dementia. BMJ 1998;317:802–8. 17. Melzer D. Personal paper. New drug treatment for Alzheimer’s disease: lessons for healthcare policy. BMJ 1998;316(7133):762–4. 18. Greenhalgh T. Advertisements for donepezil. BMJ 1997;315:1623. 19. Gray S, Wagner N. Advertisements for donepezil. BMJ 1997;314:1555–6. 20. Stein K, Milne R, Best L. Advertisements for donepezil. BMJ 1997;315:1623. 21. Melzer D, Hopkins S, Pencheon D, Brayne C, Williams R. Dementia. In: Stevens A, Raftery J, editors. Health care needs assessment. Oxford: Radcliffe Medical Press; 1994. p. 305–40. 22. Alzheimer’s Disease Society. Services for people with dementia. London; 1995. 23. Donepezil update. Drug Ther Bull 1998;36(8):60–1. 24. Donepezil. Moderate efficacy in Alzheimer’s disease. Prescrire Int 1998;7(37):146–7. 25. Stein K. Donepezil in the treatment of mild to moderate senile dementia of the Alzheimer type (SDAT). Bristol: NHS Executive South and West; 1997. Development and Evaluation Committee Report No. 69. 26. OSTEBA. Analysis of the efficacy of the treatments and cost of Alzheimer’s disease in the Basque country. 1998. 27. Regional Drug and Therapeutics Centre. New drugs for the treatment of Alzheimer’s disease. Newcastle: NHS Northern and Yorkshire; 1998. 28. Becker RE. Therapy of the cognitive deficit in Alzheimer’s disease: the cholinergic system. In: Becker RE, Giacobini E, editors. Cholinergic basis for Alzheimer therapy. Boston: Birkhauser; 1991. p. 1–30. 29. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313(7052):275–83. 30. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1–12. 31. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. York; 1999. CRD Report 4. 32. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M. Drug treatments for Alzheimer’s disease. II. A review of outcome measures in clinical trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000. 33. Deleted. 34. Deleted. 35. Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer’s disease (Cochrane Review). The Cochrane Library, Issue 4. Oxford: Update Software; 2000. 36. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, Oremus M. Drug treatments for Alzheimer’s disease. I. A comparative analysis of clinical trials. Ottawa: Canadian Coordinating Office of Health Technology Assessment (CCOHTA); 2000. 37. Livingston G, Katona C. How useful are cholinesterase inhibitors in the treatment of Alzheimer’s disease? A number needed to treat analysis. Int J Geriatr Psychiatry 2000;15(3):203–7. 38. Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walshe TM, et al. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7(6):293–303. 39. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebocontrolled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group [see comments]. Neurology 1998;50(1):136–45. 40. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, Alter M, Apter J, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158(9):1021–31. 41. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dementia Geriatr Cogn Disord 1999;10(3):237–44. 42. Greenberg SM, Tennis MK, Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000;57(1):94–9. 43. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer’s disease. The Cochrane Library, Issue 4. Oxford: Update Software; 2000. 44. Sramek JJ, Anand R, Wardle TS, Irwin P, Hartman RD, Cutler NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer’s disease. Life Sci 1996;58(15):1201–7. 45. Agid Y, Dubois B, Anand R, Gharabawi G. Efficacy and tolerability of rivastigmine in patients with dementia of the Alzheimer type. Curr Ther Res Clin Exp 1998;59(12):837–45. 46. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1(2):55–65. 47. Forette F, Anand R, Gharabawi G. A phase II study in patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon registered). Eur J Neurol 1999;6(4):423–9. 48. Rosler M, Anand R, Cicin SA, Gauthier S, Agid Y, Dal Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999;318(7184):633–40. 49. Wilcock G, Wilkinson D. Galanthamine hydrobromide: interim results of a group comparative, placebo controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Iqbal K, Winblad B, Nishimura T, Takeda M, Wiesniewski HM, editors. Alzheimer’s disease: biology, diagnosis and therapeutics. Chichester (England): Wiley; 1997. p 661–4. 50. Tariot P, Solomon PR, Morris J, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology 2000;54(June):2269–76. 51. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD. A 6-month randomised, placebo-controlled trial with a 6-month extension. Neurology 2000;54(June):2261–8. 52. Sonnenberg FA, Roberts MS, Tsevat J, Wong JB, Barry M, Kent DL. Toward a peer review process for medical decision analysis models. Med Care 1994;32(7 Suppl):JS52–JS64. 54. Stewart A, Phillips R, Dempsey G. Pharmacotherapy for people with Alzheimer’s disease: a Markov-cycle evaluation of five years’ therapy using donepezil. Int J Geriatr Psychiatry 1998;13(7):445–53. 55. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer’s disease: a Markov model. Clin Ther 1999;21(7):1230–40. 56. O’Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, et al. Economic evaluation of donepezil for the treatment of Alzheimer’s disease in Canada. J Am Geriatr Soc 1999;47(5):570–8. 57. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology 1999;52(6):1138–45. 58. Stein K. Rivastigmine (Exelon) in the treatment of senile dementia of the Alzheimer type (SDAT). Bristol: NHS Executive South and West; 1998. Development and Evaluation Committee Report No. 89. 59. Fenn P, Gray A. Estimating long term cost savings from treatment of Alzheimer’s disease: a modelling approach. Pharmacoeconomics 1999;16(2):165–74. 60. Hauber AB, Gnanasakthy A, Snyder EH, Bala MV, Richter A, Mauskopf JA. Potential savings in the cost of caring for Alzheimer’s disease – treatment with rivastigmine. Pharmacoeconomics 2000; 17(4):351–60. 61. Hauber AB, Gnanasakthy A, Mauskopf JA. Savings in the cost of caring for patients with Alzheimer’s disease in Canada: an analysis of treatment with rivastigmine. Clin Ther 2000;22(4):439–51. 62. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. Cognitive function and the costs of Alzheimer disease: an exploratory study. Arch Neurol 1997;54(6):687–93. 63. Sheldon T. Problems using modelling in the economic evaluation of health care. Health Econ 1996;5:1–11. 64. O’Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF. Users’ guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 1997;277(22):1802–6. 65. Gray A. Is the intervention cost-effective? In: Dawes M, editor. Evidence-based practice: a primer for health care professionals. Churchill Livingstone; 1999. p. 181–97. 66. Best L, Stevens A, Colin-Jones D. Rapid and responsive health technology assessment: the development and evaluation process in the South and West region of England. J Clin Effect 1997;2(2):51–6. 67. Schneider J, Kavanagh S, Knapp M, Beecham J, Netten A. Elderly people with advanced cognitive impairment in England: resource use and costs. Ageing Soc 1993;13:27–50. 68. Department of Health. Shaping the future NHS: long term planning for hospitals and related services. Consultation document on the findings of the National Bed Inquiry. London: Department of Health; 2000. 69. Netten A, Dennet J, Knight J. Unit costs of health and social care 1999. University of Kent, Canterbury: Personal and Social Services Research Unit; 1999. 70. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. London: British Medical Association & Royal Pharmaceutical Society (Great Britain); 2000. 71. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054–60. 72. Clinical evidence. BMJ Publishing Group, 1999. 73. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm A-L, et al. Donepezil enhances global function, cognition, and activities of daily living compared with placebo in a one year, double-blind trial in patients with mild to moderate Alzheimer’s disease. Int Psychogeriatr 1999;11(Suppl 1):138. 74. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging 1998;13(5):391–411. 75. Rogers SL, Doody R, Mohs R, Friedhoff LT. E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30-week phase III trial. Neurology 1996;46(2):A217 S14.001. 76. Rogers SL, Perdomo C, Friedhoff LT. Clinical benefits are maintained during long-term treatment of Alzheimers disease with acetylcholinestrase inhibitor, E2020. Eur Neuropsychopharmacol 1995;5:386. 77. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ 1994;150(6):899–913. 78. Rice DP, Fox PJ, Max W, Webber PA, Lindeman DA, Hauck WW, et al. The economic burden of Alzheimer’s disease care. Health Aff (Millwood) 1993;12(2):164–76. 79. Jonsson L, Lindgren P, Wimo A, Jonsson B, Winblad B. Costs of mini mental state examinationrelated cognitive impairment. Pharmacoeconomics 1999;16(4):409–16. 80. Hux MJ, O’Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relation between severity of Alzheimer’s disease and costs of caring. CMAJ 1998;159(5):457–65. 81. Gray A, Fenn P. Alzheimer’s disease: the burden of the illness in England. Health Trends 1993;25:31–7. 82. Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease [see comments]. JAMA 1997;277(10):806–12. 83. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care 1999;37(1):27–32.
URI:	http://wrap.warwick.ac.uk/id/eprint/50154

Request changes to a record

Actions (login required)

View Item